beractant (Survanta)

Subscribe to Selected New Research on beractant

104 relevant articles (16 outcomes, 26 trials/studies) found for this Drug

Description: a bovine lung extract that contains mostly phospholipids; modified by the addition of dipalmitoylphosphatidylcholine, palmitic acid, and tripalmitin

Also Known As:

Survanta; Abbott brand of beractant; Ross brand of beractant; surfactant-TA

Relationship Network

Drug Context: Research Results

Complex Mixtures: 314

Biological Products

beractant: 104

Experts

1.	Bancalari, Eduardo: 2 articles (04/2005 - 07/2004)
2.	Infasurf Survanta Clinical Trial Group: 1 article (08/2005)
3.	Bloom, Barry T: 1 article (08/2005)
4.	Clark, Reese H: 1 article (08/2005)
5.	Nicoski, Pamela: 1 article (06/2005)
6.	Malloy, Colleen Ann: 1 article (06/2005)
7.	Muraskas, Jonathan K: 1 article (06/2005)
8.	Bancalari, Aldo: 1 article (04/2005)
9.	d'Agostino, Ralph: 1 article (04/2005)
10.	Merritt, T Allen: 1 article (04/2005)

Related Diseases

1.	Syndrome 07/01/1991 - "The incidence of respiratory distress syndrome was also lower in Survanta-treated neonates (28.0% vs 56.9%, P less than .001), and the Survanta-treated neonates' oxygenation and ventilatory status were improved significantly at 72 hours. " 06/01/1990 - "A multicenter, prospective randomized controlled trial was performed comparing the efficacy of a single intratracheal dose of modified bovine surfactant extract (Survanta, 100 mg/kg, Abbott Laboratory, North Chicago, IL) with air placebo in preventing respiratory distress syndrome. " 06/01/2005 - "A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome." 04/01/2008 - "Moreover, the data obtained were compared with those of commercially available Surfacten (Surfactant TA) which has been clinically used for neonatal respiratory distress syndrome (NRDS) in Japan. " 06/01/2005 - "AIM: To compare the effects of beractant and poractant in neonatal respiratory distress syndrome (RDS). " Order ALL the reference details at left...
2.	Lung Diseases (Lung Disease) 12/01/1994 - "In our recent prospective randomized trial, prophylactic use of Surfactant-TA prevented the development of RDS completely, and thereby reduced the incidence of chronic lung disease (odds ratio, 0.08 (92% reduction); p = 0.016). " 07/01/1994 - "We conclude that (1) the need for four doses of Survanta (administered as per protocol) was an early marker for this postsurfactant slump and (2) bronchopulmonary dysplasia at 36 weeks' postconceptional age was a better discriminator of chronic lung disease in this low-birth-weight group." 01/01/1996 - "Although no differences were noted between Survanta- and Exosurf-treated infants regarding the primary outcome of death or chronic lung disease at 28 days of age, the significant improvement in secondary clinical outcomes suggests that Survanta is more effective than Exosurf Neonatal in the treatment of established RDS." 10/01/1997 - "Ventilatory settings were increased, as needed, until the following maximum settings were reached: FIO2 of 1.0; peak inspiratory pressure of 40 cm H2O; and intermittent mandatory ventilation of 60 breaths/min. After 2 hrs of conventional ventilation or demonstration of clinically important lung disease by failure to maintain desired blood gases on the maximum ventilatory settings, 4 mL/kg of beractant was given intratracheally. " 01/01/1996 - "Death or chronic lung disease occurred in 57% of the infants treated with Exosurf Neonatal and in 54% of those infants treated with Survanta (relative risk [RR], 0.95; 95% confidence interval [CI], 0.86 to 1.04). " Order ALL the reference details at left...
3.	Lung Injury 10/01/2006 - "Based on morphology, histopathology, white blood cell count, percentage of PMNs, and protein concentration in bronchoalveolar lavage fluid, our data showed KL(4)-surfactant, unlike vehicle or beractant, blocked neutrophil influx into alveoli and suppressed lung injury. " 10/01/2006 - "For the hyperoxic injury model, mice exposed to 80% O(2) for 6 days received an intranasal bolus of vehicle, beractant, or KL(4)-surfactant on days 3, 4, 5, and 6 of the exposure, and lungs were evaluated on day 7. Mice in the LPS-induced lung injury model received an intratracheal bolus of LPS followed by an intranasal bolus of KL(4)-surfactant or control at 1, 3, and 19 hr post-LPS challenge, and lungs were evaluated after 24 hr. To explore the mechanisms of protection, in vitro assays were performed with human and murine endothelial cell monolayers, and polymorphonuclear leukocyte (PMN) transmigration in the presence or absence of KL(4)-surfactant or lipid controls was evaluated. " 11/01/2005 - "We treated rats with lavage lung injury with a commercial lung surfactant extract derived from bovine lung (Survanta) with or without addition of PEG. " 08/01/2005 - "After lung injury by instillation of meconium, they were treated with Survanta, Survanta with HA, or control mixtures. " 06/01/1993 - "Physiologic responses and distribution of aerosolized surfactant (Survanta) in a nonuniform pattern of lung injury." Order ALL the reference details at left...
4.	Adult Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 01/01/1994 - "We report two cases of adult respiratory distress syndrome (ARDS) treated successfully with repeated doses of a bovine natural surfactant (Survanta). " 10/15/2001 - "To find whether this approach is effective in lung injuries that more closely resemble adult respiratory distress syndrome (ARDS), we have compared the use of Survanta with Survanta + PEG in two additional models of lung injury caused by either lipopolysaccharide (LPS) or HCl in adult rats. " Order ALL the reference details at left...
5.	Hyaline Membrane Disease 04/01/2002 - "We tested the hypothesis that the initial functional residual capacity (FRC) of preterm infants with hyaline membrane disease (HMD) could predict the response to surfactant replacement (Survanta, 4 mL/kg/dose), with a better initial FRC being correlated with a greater improvement in PaO2, a/A PO2 ratio, and FRC. " 06/01/1985 - "As a prelude to clinical trials with a bovine surfactant (surfactant TA), in human infants with hyaline membrane disease, pulmonary and hemodynamic changes following its instillation in premature baboons were investigated. " 03/01/2001 - "Early administration of the second dose of surfactant (beractant) in the treatment of severe hyaline membrane disease." 12/01/1989 - "We conducted a clinical trial to assess whether surfactant-TA given within the first six hours of life could improve oxygenation and reduce the ventilatory support in premature infants with hyaline membrane disease (HMD) during the first 24 hours of life. " 02/01/1988 - "Because the issue of optimal time for artificial surfactant therapy for hyaline membrane disease has not been established, the effects of treatment with a reconstituted bovine surfactant (surfactant TA) were compared at two time periods in a hyaline membrane disease model in a premature baboon. " Order ALL the reference details at left...

Related Drugs and Biologics

1.	beractant (Survanta)
2.	Exosurf (Exosurf Neonatal)
3.	Surface-Active Agents (Surfactants)
4.	Carbon Monoxide
5.	bovine surfactant preparation SF-RI 1
6.	colfosceril palmitate
7.	Oxygen
8.	calfactant
9.	Gases
10.	hydroxide ion

Related Therapies and Procedures

1.	Artificial Respiration (Mechanical Ventilation)
2.	Aftercare (After-Treatment)
3.	Extracorporeal Membrane Oxygenation (ECMO)
4.	Mechanical Ventilators (Ventilator)
5.	Microbubbles

Best Treatments:
Research Summary Report
on Syndrome

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.

Free Updates for 1 Year
All 3264 Outcomes
Top 200 Key Drugs and Biologics
Top 50 Key Therapies and Procedures
Detailed History Charts
Full Research Reference Details
Sample PDF Report on Psoriasis >>

Price:

$24.00 & Delivery via PDF download
updates for 1 year

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License Details >>

Price:

$490.00 access via web interface
1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m"
1 year subscription

Proceed to Checkout >>